Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Novo Nordisk A/S	02/26/2009

RECEIVING PARTY DATA

Name:	High Point Pharmaceuticals, LLC	
Street Address:	4170 Mendenhall Oaks Parkway	
City:	High Point	
State/Country:	NORTH CAROLINA	
Postal Code:	27265	

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	10699338
Application Number:	11270389
Application Number:	11439857
Application Number:	11440935
Application Number:	11440938
Application Number:	12147678
Application Number:	11579192
Application Number:	11579206
Application Number:	11913720
Application Number:	11914624
Application Number:	11914629

CORRESPONDENCE DATA

Fax Number: (919)484-2064

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: (919) 484-2305

PATENT REEL: 022435 FRAME: 0416

500814478

Email: brejones@wcsr.com
Correspondent Name: Brendan J. Jones
Address Line 1: P.O. Box 7037

Address Line 2: Attention: Patent Docketing
Address Line 4: Atlanta, GEORGIA 30357-0037

NAME OF SUBMITTER: Brendan J. Jones

Total Attachments: 5

source=Assignment- Novo and High Point#page1.tif source=Assignment- Novo and High Point#page2.tif source=Assignment- Novo and High Point#page3.tif source=Assignment- Novo and High Point#page4.tif source=Assignment- Novo and High Point#page5.tif

PATENT REEL: 022435 FRAME: 0417



NGBY

ASSIGNMENT

THIS ASSIGNMENT is made by Novo Nordisk A/S, a corporation organized under the laws of Denmark, having a business address at Novo Allé, DK-2880 Bagsvaerd, Denmark ("Assignor"), and High Point Pharmaceuticals, LLC, a limited liability company, having a business address at 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265, USA ("Assignee").

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby assign, sell, and transfer to Assignee, its successors and assigns, the entire right, title and interest in and to the inventions described or claimed in the patent applications listed on the attached Schedule A, and in and to said patent applications and any divisions or continuations thereof, including the right to claim priority therefrom, and any Letters Patent, obtained for said inventions in the United States and foreign countries, or issuing out of said patent applications or any such division or continuation thereof, and any reissues, reexaminations or extensions of any such Letters Patent.

Further, Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue Letters Patent for said patent applications to Assignee, as owner of the entire right, title and interest therein.

Further, said Assignor hereby represents and warrants to Assignee that Assignor has full right to convey Assignor's entire right, title and interest in and to said inventions and said patent applications, and that Assignor has not executed and will not execute any agreement in conflict herewith.

Further, Assignor hereby acknowledges that Assignor's entire beneficial interest in the patent applications is irrevocably vested in Assignee including the right to make applications for protection in all countries abroad and to claim priority under the International Convention for

Page 1 of 4

such applications and hereby assents to the making of any such applications, with or without priority claim, and of any divisional applications resulting therefrom.

IN WITNESS WHEREOF, Assignor and Assignee have caused this assignment to be duly executed as of the day and year first above written.

	ASSIGNOR:		//
By:	Novo Nordisk A/S	Ву:	Signature of Officer of Assignor
LBNS	Signature of Officer of Assignor Ole Folvig Ramsby Printed Name		Kare Shultz Printed Name
	General Cousel, SUP		Chief Operating Office Title 2-26-09
	2-26-09 Date		Date

ASSIGNEE:

High Point Pharmaceuticals, LLC

By:

Senior Vice President Legal Affairs

Q 34-09

Date

SCHEDULE A To the Assignment From

Novo Nordisk A/S

To

High Point Pharmaceuticals, LLC

1)	U.S. Patent Application Serial No. 10/699,338
,	U.S. Patent Application Serial No. 11/270,389
2)	U.S. Patent Application Serial No. 11/439,857
3)	U.S. Patent Application Bonds 11/440 935
4)	U.S. Patent Application Serial No. 11/440,935
5)	U.S. Patent Application Serial No. 11/440,938
•	U.S. Patent Application Serial No. 12/147,678
6)	U.S. Patent Application Social No. 11/579.192
7)	U.S. Patent Application Serial No. 11/579,192
8)	U.S. Patent Application Serial No. 11/579,206
,	U.S. Patent Application Serial No. 11/913,720
9)	U.S. Patent Application Serial No. 11/914,624
10)	U.S. Patent Application Services
11)	U.S. Patent Application Serial No. 11/914,629

STATE OF NORTH CAROLINA

COUNTY OF Guilford

I, the undersigned Notary Public for the aforesaid jurisdiction, do hereby certify that Anne Showalter is known to me. Anne Showalter personally appeared before me this day and confirmed that she is Senior Vice President of Legal Affairs of High Point Pharmaceuticals, LLC. She acknowledged the due execution of the foregoing instrument.

Page 4 of 4



VI-462/2009

This is to certify that Mr. Ole Falvig Ramsby and Mr. Kåre Schultz, who today in my presence at the Notarial Office approved and signed this document, pursuant to a transcript from Register of The Danish Commerce and Companies Agency (dated 24.11.2008), have powers to sign on behalf of the company Novo Nordisk A/S.

Mr. Ole Falvig Ramsby has proved his identity by presenting his passport. Mr. Kåre Schultz has proved his identity by presenting his passport.

The District Courf of Lyngby, Denmark - 26th February 2009

Lone Yalcinkaya

RECORDED: 03/23/2009

Notary Public

US PUBLICUS

PATENT

REEL: 022435 FRAME: 0422